Viatris controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2024
FDA warning letter and import alert for Indore facility
The FDA issued a warning letter and import alert concerning Viatris’s manufacturing facility in Indore, India. The agency cited deficiencies involving quality control and management of manufacturing defects. The alert affected 11 actively distributed products, while four products received conditional exemptions because of shortage concerns. Viatris stated that corrective and preventive actions had been taken.